Ai-driven platform for antifungal peptide discovery from microbial isolates
Chemia Biosciences offers an AI-driven platform to discover antifungal peptides from microbial isolates. Utilizing machine learning and mass spectrometry, this technology identifies novel peptides with strong antifungal activity, demonstrating safety in vitro and in vivo.
Overview
Chemia Biosciences has developed an innovative platform that leverages artificial intelligence to revolutionize the discovery of antifungal peptides from microbial isolates. Traditional methods of natural product-based drug discovery are often cumbersome and inefficient. Our platform utilizes computational analysis of microbial genomics combined with mass spectrometry data to effectively identify novel antifungal peptides. This method significantly accelerates the discovery process and enhances the identification of bioactive compounds, as demonstrated by the successful isolation of Edaphochelin, a peptide with potent antifungal activity.
Technical specifications
- Machine Learning Application: Utilizes advanced algorithms to predict antifungal activity of peptide natural products.
- Data Utilization: Analyzes mass spectrometry data from 1500 Streptomyces cultures to identify novel compounds.
- Purification and Testing: Employs HPLC-based purification for isolating peptides; in vitro and in vivo testing confirm safety and efficacy.
- Notable Discovery: Edaphochelin, with minimum inhibitory concentrations of 0.5-2 µg/mL, shows strong antifungal activity without toxicity to human cell lines or mice.
Technology readiness level
The platform has reached a Technology Readiness Level of 5, indicating that it has been validated in a relevant environment with plans for further testing. Future work includes training the machine learning model for broader applications against molds and yeasts, with a focus on identifying peptides that maintain efficacy in acidic environments.
About Chemia Biosciences
Chemia Biosciences is a biotechnology company founded in 2021 that specializes in the discovery of bioactive small molecules for drug-resistant diseases and agricultural crop protection. Spun out of the Carnegie Mellon University School of Computer Science, the company leverages a proprietary platform that integrates AI-enabled genome mining with a specialized metabolomics search engine. This technology allows the team to rapidly scan microbial organisms to identify novel chemical structures and biological activities that are frequently undetectable through traditional discovery methods. By combining genomics and metabolomics, Chemia Biosciences works to solve the challenges of chemical novelty and diversity inherent in natural product research.
The company serves as a partner in pharmaceutical and agrochemical development, focusing on the identification of drug leads and novel fungicides. Its approach addresses the limitations of conventional, labor-intensive natural product screening by predicting microbial potential for producing specific, high-value compounds. Supported by federal research grants, including awards from the NIH and DOE, Chemia Biosciences actively engages in the discovery and optimization of bioactive molecules, aiming to provide sustainable and effective solutions for medicine and environmental health. Through its computational methods, the organization provides a scalable pipeline for identifying compounds with novel modes of action.
delivered to your inbox.